Tissue Regenix Group plc is a United Kingdom-based medical devices company in the field of regenerative medicine. The Company is engaged in the development of regenerative products to make replacement body parts using biological (human & animal) materials, using platform technologies in the field of tissues engineering and regenerative medicine. The Company has developed decellularisation (dCELL) technology, which removes DNA and other cellular material from tissue leaving an acellular scaffold which is not rejected by the patient’s body. The applications of dCELL address critical clinical needs such as wound care, heart valve replacement and knee repair. The company has developed DermaPure, a decellularized human dermis product, which replaces human dermis with human dermis, to most closely approximate the structure and function of the native tissue it is replacing.
http://www.tissueregenix.com/© 2026 J2T Services Ltd
J2T Services Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by J2T SERVICES LTD.
Registration Number: HE 341520
Address: J2T Services Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer: All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
